Additional late non-CH mutations are found in 68.4% of the AITL/PTCL-NOS in our cohort, consistent with the belief that CH-associated TET2 and DNMT3A mutations are insufficient for tumorigenesis and additional genetic alterations are required. Here, C4B is linked to angioimmunoblastic T-cell lymphoma.